Anti-inflammatory effect of aprotinin: a meta-analysis.
It is important to define the extent, and any limitations, of potential anti-inflammatory regimens used in cardiac surgery to guide the rational combination of drugs to suppress the systemic inflammatory response. Aprotinin (Trasylol) is an anti-fibrinolytic agent with reported anti-inflammatory properties. In this study, we investigated the published data on aprotinin's effect on acute phase protein and cytokine levels in cardiac surgery patients. Randomized placebo-controlled trials of aprotinin published between 1985 and 2007, in adult cardiac surgery using cardiopulmonary bypass, reporting tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-8, and IL-10 levels were included for review. Two independent reviewers graded each paper and collected information on inflammatory markers. RevMan 4.3 statistical software was used to calculate and plot the weighted mean difference between placebo and aprotinin groups. Thirteen studies met the review criteria. None of the inflammatory markers were reduced by high-dose aprotinin treatment. Low-dose aprotinin significantly reduced IL-10 levels after protamine administration (-41.3 pg/ mL; 95% CI: -59.5, -23.1), but this result was gone by the first post-operative day. These meta-analyses showed no significant effect of aprotinin on acute phase proteins or systemic cytokine markers of inflammation during clinical adult cardiac surgery using cardiopulmonary bypass. While recognizing that other host defense systems, such as coagulation and complement, contribute to the overall systemic inflammatory response, the evidence presented here does not support the clinical use of aprotinin as an anti-inflammatory agent on its own.
Brown
Jeremiah R
JR
The Dartmouth Institute for Health Policy and Clinical Practice and Dartmouth Medical School, Lebanon, New Hampshire 03756, USA. jbrown@Dartmouth.edu
Toler
Andrew W J
AW
Kramer
Robert S
RS
Landis
R Clive
RC
D000209:Acute-Phase Proteins / Q000378:metabolism*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D007611:Aprotinin / Q000494:pharmacology*; D006348:Cardiac Surgical Procedures; D016207:Cytokines / Q000378:metabolism*; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D016032:Randomized Controlled Trials as Topic
D000209:Acute-Phase Proteins; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D018836:Inflammation Mediators; D007611:Aprotinin
J Thorac Cardiovasc Surg. 2001 Jul;122(1):123-8
11436044
J Thorac Cardiovasc Surg. 1993 Jul;106(1):1-9; discussion 9-10
7686593
J Cardiothorac Vasc Anesth. 2000 Dec;14(6):682-6
11139109
J Card Surg. 2006 Jul-Aug;21(4):336-41
16846409
N Engl J Med. 2006 Jan 26;354(4):353-65
16436767
Cochrane Database Syst Rev. 2001;(1):CD001886
11279735
Ann Thorac Surg. 2006 Feb;81(2):619-24
16427862
Cardiovasc Drugs Ther. 2002 Jan;16(1):37-42
12085976
BMJ. 2003 Sep 6;327(7414):557-60
12958120
J Thorac Cardiovasc Surg. 2003 Jan;125(1):32-5
12538980
Anesth Analg. 2001 Apr;92(4):830-6
11273910
Ann Thorac Surg. 2004 Feb;77(2):644-50
14759453
J Thorac Cardiovasc Surg. 2004 Sep;128(3):442-8
15354106
Anesth Analg. 2004 Feb;98(2):285-290
14742356
Thorac Cardiovasc Surg. 1999 Apr;47(2):111-8
10363611
Arzneimittelforschung. 1983;33(4):479-94
6191764
J Extra Corpor Technol. 2007 Dec;39(4):281-4
18293820
Cardiovasc Drugs Ther. 2003 Jul;17(4):343-8
14618096
Ann Thorac Surg. 1993 Feb;55(2):552-9
8431082
Control Clin Trials. 1996 Feb;17(1):1-12
8721797
J Extra Corpor Technol. 2007 Dec;39(4):291-5
18293823
Lancet. 1999 Nov 27;354(9193):1896-900
10584742
Am J Pathol. 1982 Oct;109(1):15-26
6181692
Anesthesiology. 2004 Feb;100(2):225-33
14739793
J Cardiothorac Vasc Anesth. 2001 Oct;15(5):603-10
11688002
J Thorac Cardiovasc Surg. 2004 Jul;128(1):83-91
15224025
J Cardiothorac Vasc Anesth. 1997 Feb;11(1):29-31
9058216
Semin Cardiothorac Vasc Anesth. 2006 Jun;10(2):132-42
16959740
J Thorac Cardiovasc Surg. 2008 May;135(5):999-1006
18455576
Ann Thorac Surg. 2000 Apr;69(4):1192-7
10800818
Heart Surg Forum. 2008;11(5):E316-22
19131308
Circulation. 2001 Sep 18;104(12 Suppl 1):I265-9
11568067
N Engl J Med. 2008 May 29;358(22):2319-31
18480196
J Cardiovasc Pharmacol. 2007 Jan;49(1):39-45
17261962
Ann Thorac Surg. 1998 Jan;65(1):66-9
9456097
J Thorac Cardiovasc Surg. 2008 Mar;135(3):487-91
18329457
Cardiovasc Surg. 2001 Aug;9(4):403-6
11420167
Ann Thorac Surg. 2003 Jan;75(1):210-5; discussion 215-6
12537218
Ann Thorac Surg. 1998 Sep;66(3):747-53; discussion 753-4
9768925
Ann Thorac Surg. 2000 Apr;69(4):1084-91
10800798
Perfusion. 2000 Nov;15(6):495-9
11131212
J Thorac Cardiovasc Surg. 2006 Jan;131(1):21-7
16399290
Ann Thorac Surg. 1997 Jan;63(1):50-6
8993240
J Thorac Cardiovasc Surg. 1995 Dec;110(6):1658-62
8523876
Scand Cardiovasc J. 2001 Feb;35(1):50-4
11354573
J Thorac Cardiovasc Surg. 2003 Nov;126(5):1498-503
14666025
J Thorac Cardiovasc Surg. 2003 Jan;125(1):184-90
12539003